UCB, the multinational biopharmaceutical company headquartered in Brussels, Belgium. and CDMO Samsung Biologics of South Korea have expanded their seven-year partnership with a new drug substance manufacturing deal worth 382 billion Korean won ($353 million). The partnership involves Samsung Biologics manufacturing several
Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has entered into a strategic partnership with LegoChem Biosciences, a biotech company at the forefront of the research and development of antibody-drug conjugate (ADC) programs. This partnership was announced on February 7,
Samsung Biologics is a Contract Service, CMO/CDMO, Biopharmaceutical company company operating in the pharmaceutical industry. Samsung Biologics is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
